Menopur

Menotrophin, the active ingredient in Menopur, is a gonadotropin (FSH and LH preparation) presented as an injectable solution for subcutaneous administration. It is employed to treat infertility caused by anovulation and to support ovarian follicular development in assisted reproductive technology cycles, including in vitro fertilisation protocols.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide with full regulatory support and cold‑chain logistics where required, and ensuring compliance with local import regulations.

Menopur, a gonadotropin preparation, acts on the reproductive hormone pathway to facilitate ovarian stimulation in fertility treatment.

- Infertility due to anovulation: stimulates follicular development to enable ovulation. - Controlled ovarian hyperstimulation for IVF/ART: provides combined FSH/LH activity to produce multiple mature oocytes. - Induction of ovulation in assisted reproductive technology: facilitates timed ovulation for embryo transfer. - Oocyte donation cycles: enhances follicular response to obtain high‑quality donor oocytes.

Menopur may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Injection site pain or erythema. - Mild abdominal discomfort or bloating. - Nausea or mild headache. - Breast tenderness.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS), potentially severe. - Multiple pregnancy, increasing obstetric risk. - Severe allergic reactions, including anaphylaxis. - Thromboembolic events or significant abdominal pain. - Vision changes or sudden swelling. - Severe abdominal distension with rapid weight gain.

Careful patient assessment and monitoring are essential when using Menopur.

- Patient selection: evaluate ovarian reserve and prior response before initiating therapy. - Monitoring: perform regular ultrasound and estradiol assessments to adjust dose. - OHSS risk: avoid in patients with polycystic ovary syndrome or high estradiol levels. - Pregnancy testing: confirm negative pregnancy before starting treatment. - Patient counseling: discuss signs of OHSS and when to seek medical attention. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur can interact with other medications that affect ovarian response or bleeding risk.

Major Interactions (Avoid): - Concurrent GnRH agonists: may amplify ovarian response and increase OHSS risk. - High‑dose estrogen therapy: can exacerbate ovarian stimulation. - Other gonadotropins: combined use may lead to excessive follicular development.

Moderate Interactions (Monitor Closely): - Corticosteroids: may alter hormonal response, requiring dose adjustment. - Anticoagulants: monitor for increased bruising at injection sites. - Antihistamines: may mask early signs of allergic reactions.